First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor Demonstrates that Abelacimab, if Approved, Could Offer Significant Cost Savings as Compared to a Current Standard of Care Anticoagulant
Le Lézard,
Results of the first-ever cost-effectiveness study of a Factor XI inhibitor were presented today during sessions of the…